Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Rhea-AI Summary

Aditxt (NASDAQ: ADTX) has announced a virtual Fireside Chat scheduled for Friday, February 21, 2025, at 11:30 AM Eastern Time. CEO Amro Albanna will lead the session, providing updates on key corporate developments and the company's pipeline.

The discussion will focus on two main areas: Adimune, a subsidiary working on autoimmune conditions including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome, and Pearsanta's early cancer detection program and its planned IPO for 2025.

Participants can submit questions via email to engagement@aditxt.com by February 20th at 5:00 PM ET. Registration is available through the provided Zoom webinar link.

Co-founder and CEO Amro Albanna to Provide a Company Update Followed by Q&A Session

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on Friday, February 21, 2025, at 11:30 AM Eastern Time. The event will feature Amro Albanna, CEO of Aditxt, who will provide updates on key corporate developments, including the status of current subsidiaries, potential transactions, and notable advancements in the Company's pipeline.

During the session, Amro Albanna will discuss developments within Adimune, Inc., a subsidiary focused on autoimmunity including the treatment of Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.

Additionally, the discussion will cover Pearsanta's developments in its early cancer detection program and its planned Initial Public Offering (IPO) targeted for 2025.

Participants are invited to engage directly with the Company by submitting questions via email by February 20th at 5:00 PM ET to engagement@aditxt.com.

Registration details are available at https://us06web.zoom.us/webinar/register/WN_UBF3sZwCRh2WMra0TikKEg.

About Aditxt

Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. On December 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

For more information, www.aditxt.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; expected usage of the Company’s ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213581038/en/

Corporate Communications

Jeff Ramson, PCG Advisory

T: 646-863-6893

jramson@pcgadvisory.com

Source: Aditxt, Inc.

FAQ

When is Aditxt's (ADTX) upcoming Fireside Chat scheduled for 2025?

Aditxt's Fireside Chat is scheduled for Friday, February 21, 2025, at 11:30 AM Eastern Time.

What topics will be covered in Aditxt's (ADTX) February 2025 Fireside Chat?

The Fireside Chat will cover updates on corporate developments, subsidiary status, potential transactions, Adimune's autoimmunity treatments, and Pearsanta's cancer detection program and planned IPO.

What medical conditions is Aditxt's (ADTX) subsidiary Adimune focusing on?

Adimune is focusing on autoimmune conditions including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.

When is Aditxt's (ADTX) subsidiary Pearsanta planning its IPO?

Pearsanta is targeting an Initial Public Offering (IPO) for 2025.

How can investors submit questions for Aditxt's (ADTX) February 2025 Fireside Chat?

Investors can submit questions via email to engagement@aditxt.com by February 20th at 5:00 PM ET.